Literature DB >> 12499172

Contribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of Streptococcus pneumoniae.

Ryuta Kishii1, Masaya Takei, Hideyuki Fukuda, Katsuhiko Hayashi, Masaki Hosaka.   

Abstract

The inhibitory activities (50% inhibitory concentrations [IC(50)s]) of gatifloxacin and other quinolones against both DNA gyrase and topoisomerase IV of the wild-type Streptococcus pneumoniae IID553 were determined. The IC(50)s of 10 compounds ranged from 4.28 to 582 microg/ml against DNA gyrase and from 1.90 to 35.2 microg/ml against topoisomerase IV. The inhibitory activity against DNA gyrase was more varied than that against topoisomerase IV among fluoroquinolones. The IC(50)s for DNA gyrase of the 8-methoxy quinolones gatifloxacin and AM-1147 were approximately seven times lower than those of their 8-H counterparts AM-1121 and ciprofloxacin, whereas the IC(50)s for topoisomerase IV were 1.5 times lower. Moreover, the IC(50) ratios (IC(50) for DNA gyrase/IC(50) for topoisomerase IV) of gatifloxacin, AM-1147, and moxifloxacin, which possess 8-methoxy groups, were almost the same. The 8-methoxy quinolones showed higher antibacterial activity and less mutant selectivity against IID553 than their 8-H counterparts. These results suggest that the 8-methoxy group enhances both target inhibition, especially for DNA gyrase, leading to potent antipneumococcal activity and dual inhibition against both DNA gyrase and topoisomerase IV in the bacterial cell.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12499172      PMCID: PMC148977          DOI: 10.1128/AAC.47.1.77-81.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

Authors:  J M Blondeau; X Zhao; G Hansen; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus.

Authors:  Y Dong; X Zhao; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

3.  Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.

Authors:  H Fukuda; R Kishii; M Takei; M Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 4.  Mechanisms of action of antimicrobials: focus on fluoroquinolones.

Authors:  D C Hooper
Journal:  Clin Infect Dis       Date:  2001-03-15       Impact factor: 9.079

5.  Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group.

Authors:  T Lu; X Zhao; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

6.  Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.

Authors:  S Roychoudhury; C E Catrenich; E J McIntosh; H D McKeever; K M Makin; P M Koenigs; B Ledoussal
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

7.  Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis.

Authors:  Y Dong; X Zhao; B N Kreiswirth; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

8.  In vitro antimicrobial activity of gatifloxacin against 873 clinical isolates from respiratory tract, urinary tract and surgical infections during 1997-1998 in Japan.

Authors:  Y Tsurumaki; H Manda; M Takei; M Hosaka
Journal:  J Antimicrob Chemother       Date:  2000-05       Impact factor: 5.790

Review 9.  Mechanisms of action and resistance of older and newer fluoroquinolones.

Authors:  D C Hooper
Journal:  Clin Infect Dis       Date:  2000-08       Impact factor: 9.079

10.  Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.

Authors:  V J Heaton; J E Ambler; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

View more
  6 in total

1.  In Vitro Activity of Lascufloxacin against Streptococcus pneumoniae with Mutations in the Quinolone Resistance-Determining Regions.

Authors:  Mika Murata; Kosuke Kosai; Shunsuke Yamauchi; Daisuke Sasaki; Norihito Kaku; Naoki Uno; Yoshitomo Morinaga; Hiroo Hasegawa; Taiga Miyazaki; Koichi Izumikawa; Hiroshi Mukae; Katsunori Yanagihara
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 2.  Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Authors:  Susan J Keam; Katherine F Croom; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Contribution of topoisomerase IV mutation to quinolone resistance in Mycoplasma genitalium.

Authors:  Yuko Yamaguchi; Masaya Takei; Ryuta Kishii; Mitsuru Yasuda; Takashi Deguchi
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

4.  Reactive Oxygen Species Contribute to the Bactericidal Effects of the Fluoroquinolone Moxifloxacin in Streptococcus pneumoniae.

Authors:  M J Ferrándiz; A J Martín-Galiano; C Arnanz; T Zimmerman; A G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

Review 5.  Quinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance.

Authors:  Natassja G Bush; Isabel Diez-Santos; Lauren R Abbott; Anthony Maxwell
Journal:  Molecules       Date:  2020-12-01       Impact factor: 4.411

Review 6.  Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities.

Authors:  Temilolu Idowu; Frank Schweizer
Journal:  Antibiotics (Basel)       Date:  2017-11-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.